| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Empaveli, Aspaveli; fka APL-2 | |
| 3 | Generic | pegcetacoplan | |
| 4 | Indication | PNH, Geographic Atrophy | |
| 5 | Economics | Sobi in Europe | |
| 6 | MOA | C3 inhibitor | |
| 7 | Administration | subcutaneous twice weekly 1080mg | |
| 8 | Competition | ||
| 9 | Clinical Trials | ||
| 10 | |||
| 11 | |||
| 12 | Phase III "PRINCE" n=53 treatment-naïve PNH - NCT04085601 | ||
| 13 | |||
| 14 | |||
| 15 | |||
| 16 | Phase III "PEGASUS" n=80 PNH - NCT03050549 | ||
| 17 | |||
| 18 | |||
| 19 | |||
| 20 | |||
| 21 | Phase III "VALIANT" IC-MPGN/C3G | ||
| 22 | |||
| 23 | |||
| 24 | |||
| 25 | Phase II "MERIDIAN" ALS |